Baker Bros. Advisors LP Bicycle Therapeutics PLC Transaction History
Baker Bros. Advisors LP
- $9.86 Billion
- Q2 2025
A detailed history of Baker Bros. Advisors LP transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Baker Bros. Advisors LP holds 10,885,357 shares of BCYC stock, worth $78.6 Million. This represents 0.77% of its overall portfolio holdings.
Number of Shares
10,885,357
Previous 10,885,357
-0.0%
Holding current value
$78.6 Million
Previous $92.4 Million
18.14%
% of portfolio
0.77%
Previous 1.1%
Shares
5 transactions
Others Institutions Holding BCYC
# of Institutions
113Shares Held
41.9MCall Options Held
111KPut Options Held
16.6K-
Fcpm Iii Services B.V. Naarden, P73.45MShares$24.9 Million6.5% of portfolio
-
Armistice Capital, LLC New York, NY2.8MShares$20.2 Million0.34% of portfolio
-
Westfield Capital Management CO LP Boston, MA2.66MShares$19.2 Million0.12% of portfolio
-
Siren, L.L.C. New York, NY2.01MShares$14.5 Million0.72% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.77MShares$12.8 Million0.03% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $214M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...